Better approach needed to detect and treat military personnel with adverse effects from mefloquineBMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i838 (Published 10 February 2016) Cite this as: BMJ 2016;352:i838
- Jane C Quinn, senior lecturer
- Charles Sturt University, Wagga Wagga, NSW 2678 Australia
The use of mefloquine in militarny personnel has long been controversial.1 Recent evidence presented to the current defence select committee inquiry called mefloquine the “least safe of the available antimalarial regimens currently used,”2 yet anecdotal evidence suggests that mefloquine has been routinely issued without an individual risk assessment for several decades. The Ministry of Defence (MOD) admitted that defined protocols for prescribing mefloquine had been available since 1997, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial